Role of Patient’s Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

by VV Strugov, EA Stadnik, YuV Virts, TO Silina, AYu Zaritskii
Published 2016-04-01

Role of Superficial CD200 Marker in Differential Diagnosis of Malignant B-Cell Lymphoproliferative Diseases

by YuV Mirolyubova, EA Stadnik, TS Nikulina, VV Strugov, TO Andreeva, YuV Virts, RV Grozov, AYu Zaritskey
Published 2017-04-01

Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia

by VV Strugov, EA Stadnik, AM Rumyantsev, TO Andreeva, YuV Virts, YuV Mirolyubova, PA Butylin, AYu Zaritskey
Published 2017-04-01

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia

by YuV Mirolyubova, EA Stadnik, VV Strugov, TO Andreeva, TS Nikulina, YuV Virts, PA Butylin, AG Rumyantsev, AYu Zaritskey
Published 2018-04-01

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia

by E A Stadnik, V V Strugov, T O Andreeva, Yu V Virts, Yu V Mirolyubova, P A Butylin, A Yu Zaritskiy
Published 2016-12-01

Modern therapy and prognostic factors at chronic lymphoid leucosis. Review of literature and own datas

by Ye. A. Stadnik, Ye. A. Nikiteen, Yu. A. Alekseyeva, G. N. Salogub, M. A. Yakubovich, Yu. V. Virts, A. Yu. Zaritsky
Published 2008-12-01

Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study

by E A Stadnik, V V Strugov, T O Andreeva, Yu V Virts, A M Rumyantsev, Yu V Mirolyubova, P A Butylin, A Yu Zaritsky
Published 2017-07-01